ClinicalTrials.gg
DrugRead study by study

Osimertinib clinical trials

Also written AZD9291 and Tagrisso.

studies test it
130
open now
28
in phase 3
19
first study started
2013
ClinicalTrials.gov finds 393 studies for osimertinib. How that becomes 130 here

Every study that search finds has been read, apart from the 1 newest, to see whether and how it gives osimertinib. ClinicalTrials.gov counts as of Nov 17, 2026. How drug pages count

  1. 393Found by its intervention search · See all 393 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 302 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
  2. −35
    Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
  3. 358Give osimertinib to participants
  4. −58Observe patients on it, or give it outside a trial
  5. −2Use it as a tool: an imaging tracer or a test of drug response
  6. −17Compare another treatment with it
  7. −151Give it beside what is tested
  8. 130Test it: the count on this site

Get an email when these change. Save the osimertinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
13 Nov 2015 · TAGRISSO · NDA 208065 (FDA, Drugs@FDA)
European Union
1 Feb 2016 · Tagrisso · EMEA/H/C/004124 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Osimertinib
71
Mereletinib
8
AZD9291 tablet dosing
5
AZD9291; TAGRISSO
2
Tagrisso, AZD9291
2

Brand

Tagrisso
32
Tagrisso 80mg
1

Development codes

AZD9291
39

Studies by the year they started

129 studies that test it; most in 2018 (16); 1 more planned to start later

Studies that test osimertinib, by start year
YearStudies
20132
201413
201512
201612
20178
201816
20198
202011
202110
202212
20237
20249
20253
20266

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
33
Phase 2
77
Phase 3
19
Phase 4
4
No phase
4

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 46 · Other 84

AstraZeneca (43) · National Cancer Institute (NCI) (4) · Samsung Medical Center (4) · Jonsson Comprehensive Cancer Center (3) · Memorial Sloan Kettering Cancer Center (3) · Qingdao Central Hospital (3) · Dana-Farber Cancer Institute (2) · Eli Lilly and Company (2)

Often tested with

Tested in the same studies.

Durvalumab (6) · Pemetrexed (5) · Carboplatin (4) · Afatinib (3) · Capivasertib (3) · Crizotinib (3) · Necitumumab (3) · Dacomitinib (3)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 5 phase 3 studies under way

Osimertinib is the comparator. A study of two new drugs counts under both.

  • 2Aflutinib · ArriVent BioPharma, Inc., Allist Pharmaceuticals, Inc. · next primary completion Feb 2029
  • 1Amivantamab · Janssen Research & Development, LLC
  • 1Lazertinib · Janssen Research & Development, LLC
  • 1ASKC202 · Jiangsu Aosaikang Pharmaceutical Co., Ltd. · next primary completion Dec 2030
  • 1EGFR Inhibitor TY-9591 · TYK Medicines, Inc
New treatments tested with it · 8 most studied

New when their studies opened, with osimertinib beside them; studies of each.

Reaching primary completion within a year · 14, 2 in phase 3

Studies that test osimertinib, phase 3 first.

Studies

Open first, then newest update. How each study uses osimertinib has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.

Testing it · 130

See all 130 studies that test osimertinib →

Behind its US label · 5 — the studies the FDA label of TAGRISSO describes

From the Clinical Studies section of TAGRISSO (2024-09), as openFDA has it. A study the site does not hold is left out.

Tested on its own · 65 — no other medicine in its arm

Showing 20 of 65. See all 65 →

Tested with established drugs · 11 — they are given beside it
Tested in a combination · 54 — another drug in the study is under test too

Showing 20 of 54. See all 54 →

Beside an established treatment under test · 42 — an approved drug, surgery or radiation is what the study tests

Tested with osimertinib: Radiation 13 · Surgery or a procedure 8 · Pemetrexed 5 · Bevacizumab 4 · Carboplatin 3 · Aspirin 2 · Cisplatin 1 · Ramucirumab 1

Showing 20 of 42. See all 42 →

Beside a new treatment under test · 104 — a new drug, cell therapy or vaccine is what the study tests

New treatments tested with osimertinib: izalontamab brengitecan 7 · becotatug 5 · sacituzumab tirumotecan 4 · savolitinib 4 · glumetinib 4 · sapanisertib 2 · datopotamab deruxtecan 2 · vebreltinib 2

Showing 20 of 104. See all 104 →

Beside supportive care · 1 — a supportive treatment or test is studied
One option of several · 3 — a test or a strategy chooses among drugs
Given beside what is tested · 1 — usual care or a partner of the new treatment
As the comparator · 17 — what is tested is compared with osimertinib
Observed · 58 — patients on it are followed, or it is given outside a trial

Showing 20 of 58. See all 58 →

As a tool · 2 — an imaging tracer or a test of drug response

Codes

What other systems call osimertinib · ClinicalTrials.gg INT000195

  • MeSH (NLM) C000596361osimertinibConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 3C06JJ0Z2OOSIMERTINIBConfirmed FDA, NLM, Wikidata
  • RxNorm 1721560Confirmed FDA, Wikidata
  • Wikidata Q21506464osimertinibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C116377OsimertinibOne source FDA
  • DrugBank DB09330One source Wikidata

Also registered as osimertinib mesylate (UNII RDL94R2A16 · RxNorm 1721559).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.

Start the discussion